These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 28960391)

  • 1. Multicentre clinical evaluation of the new highly sensitive Elecsys® thyroglobulin II assay in patients with differentiated thyroid carcinoma.
    Trimboli P; Imperiali M; Piccardo A; CampennÌ A; Giordani I; Ruggeri RM; Baldari S; Orlandi F; Giovanella L
    Clin Endocrinol (Oxf); 2018 Feb; 88(2):295-302. PubMed ID: 28960391
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical relevance of highly sensitive Tg assay in monitoring patients treated for differentiated thyroid cancer.
    Iervasi A; Iervasi G; Ferdeghini M; Solimeo C; Bottoni A; Rossi L; Colato C; Zucchelli GC
    Clin Endocrinol (Oxf); 2007 Sep; 67(3):434-41. PubMed ID: 17555505
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum Basal thyroglobulin measured by a second-generation assay correlates with the recombinant human thyrotropin-stimulated thyroglobulin response in patients treated for differentiated thyroid cancer.
    Spencer C; Fatemi S; Singer P; Nicoloff J; Lopresti J
    Thyroid; 2010 Jun; 20(6):587-95. PubMed ID: 20470203
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discordance in thyroglobulin measurements by radioimmunoassay and immunometric assay: a useful means of identifying thyroglobulin assay interference.
    Crane MS; Strachan MW; Toft AD; Beckett GJ
    Ann Clin Biochem; 2013 Sep; 50(Pt 5):421-32. PubMed ID: 23847033
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of the highly sensitive Roche thyroglobulin II assay and establishment of a reference limit for thyroglobulin-negative patient samples.
    Rotteveel-de Groot DM; Ross HA; Janssen MJR; Netea-Maier RT; Oosting JD; Sweep FCGJ; van Herwaarden AE
    Pract Lab Med; 2016 Aug; 5():6-13. PubMed ID: 28856198
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Highly sensitive serum thyroglobulin and circulating thyroglobulin mRNA evaluations in the management of patients with differentiated thyroid cancer in apparent remission.
    Fugazzola L; Mihalich A; Persani L; Cerutti N; Reina M; Bonomi M; Ponti E; Mannavola D; Giammona E; Vannucchi G; di Blasio AM; Beck-Peccoz P
    J Clin Endocrinol Metab; 2002 Jul; 87(7):3201-8. PubMed ID: 12107225
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An evaluation of the value of first thyroglobulin determination in the diagnostics of metastases immediately following differentiated thyroid carcinoma surgery.
    Makarewicz J; Adamczewski Z; Rutkowski A; Mikosiński S; Knapska-Kucharska M; Gonerska-Szadkowska A; Oszukowska L; Karwowska A; Lewiński A
    Endokrynol Pol; 2006; 57(4):370-3. PubMed ID: 17006838
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multi-center evaluation of the highly sensitive Abbott ARCHITECT and Alinity thyroglobulin chemiluminescent microparticle immunoassay.
    Evans C; Lotz J; Bhandari M; Hellier RT; Wang XY; Lott R; Lackner KJ; Müller R; Kulasingam V
    J Clin Lab Anal; 2022 Sep; 36(9):e24595. PubMed ID: 35837992
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Measuring thyroglobulin in patients with thyroglobulin autoantibodies: evaluation of the clinical impact of BRAHMS Kryptor® Tg-minirecovery test in a large series of patients with differentiated thyroid carcinoma.
    Giovanella L; Verburg FA; Trimboli P; Imperiali M; Keller F; Ceriani L
    Clin Chem Lab Med; 2019 Jul; 57(8):1185-1191. PubMed ID: 30835250
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thyroglobulin measurement before rhTSH-aided 131I ablation in detecting metastases from differentiated thyroid carcinoma.
    Giovanella L; Ceriani L; Suriano S; Ghelfo A; Maffioli M
    Clin Endocrinol (Oxf); 2008 Oct; 69(4):659-63. PubMed ID: 18363882
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-sensitive basal serum thyroglobulin 6-12 months after thyroid ablation is strongly associated with early response to therapy and event-free survival in patients with low-to-intermediate risk differentiated thyroid carcinomas.
    Trimboli P; Zilioli V; Imperiali M; Ceriani L; Giovanella L
    Eur J Endocrinol; 2017 May; 176(5):497-504. PubMed ID: 28137736
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison between a new thyroglobulin assay with the well-established Beckman Access immunoassay: A preliminary report.
    Cennamo M; La Civita E; Curci A; Liotti A; Braschi U; Terracciano D
    J Clin Lab Anal; 2021 Feb; 35(2):e23589. PubMed ID: 32951246
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A sensitive Tg assay or rhTSH stimulated Tg: what's the best in the long-term follow-up of patients with differentiated thyroid carcinoma?
    Persoon AC; Jager PL; Sluiter WJ; Plukker JT; Wolffenbuttel BH; Links TP
    PLoS One; 2007 Aug; 2(8):e816. PubMed ID: 17726546
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serial post-surgical stimulated and unstimulated highly sensitive thyroglobulin measurements in low- and intermediate-risk papillary thyroid carcinoma patients not receiving radioactive iodine.
    Kashat L; Orlov S; Orlov D; Assi J; Salari F; Walfish PG
    Endocrine; 2016 Nov; 54(2):460-466. PubMed ID: 27189148
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thyroglobulin as early prognostic marker to predict remission at 18-24 months in differentiated thyroid carcinoma.
    González C; Aulinas A; Colom C; Tundidor D; Mendoza L; Corcoy R; Mato E; Alcántara V; Urgell Rull E; de Leiva A
    Clin Endocrinol (Oxf); 2014 Feb; 80(2):301-6. PubMed ID: 23826916
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thyroglobulin and thyroglobulin antibodies: assay-dependent management consequences in patients with differentiated thyroid carcinoma.
    van Kinschot CMJ; Peeters RP; van den Berg SAA; Verburg FA; van Noord C; van Ginhoven TM; Visser WE
    Clin Chem Lab Med; 2022 Apr; 60(5):756-765. PubMed ID: 35108464
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular technology and the recombinant TSH have changed diagnostics of thyroid carcinoma with positive I-131 whole body scan but low serum thyroglobulin.
    Montella L; Caraglia M; Abbruzzese A; Soricelli A; Prete SD; Squame G; Salvatore M
    Exp Mol Med; 2004 Jun; 36(3):268-73. PubMed ID: 15272239
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the diagnostic value of the first thyroglobulin determination in detecting metastases after differentiated thyroid carcinoma surgery.
    Makarewicz J; Adamczewski Z; Knapska-Kucharska M; Lewiński A
    Exp Clin Endocrinol Diabetes; 2006 Oct; 114(9):485-9. PubMed ID: 17115345
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thyroglobulin assay during thyroxine treatment in low-risk differentiated thyroid cancer management: comparison with recombinant human thyrotropin-stimulated assay and imaging procedures.
    Giovanella L; Ceriani L; Ghelfo A; Keller F; Sacchi A; Maffioli M; Spriano G
    Clin Chem Lab Med; 2006; 44(5):648-52. PubMed ID: 16681439
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Cut-Off Level of Recombinant Human TSH-Stimulated Thyroglobulin in the Follow-Up of Patients with Differentiated Thyroid Cancer.
    Kowalska A; Pałyga I; Gąsior-Perczak D; Walczyk A; Trybek T; Słuszniak A; Mężyk R; Góźdź S
    PLoS One; 2015; 10(7):e0133852. PubMed ID: 26230494
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.